drugset / Trial / NCT05084677
Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and tolerance of adding toripalimab simultaneously and subsequently to concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |